Cleared Traditional

K932877 - DIASTAT ANTI-CENTROMERE KIT

K932877 is an FDA 510(k) clearance for DIASTAT ANTI-CENTROMERE KIT, manufactured by Shield Diagnostics, Ltd.. The device is a Class 2 Immunology device with product code LLL cleared through the Traditional 510(k) pathway after a 123-day FDA review.

K932877 · Shield Diagnostics, Ltd. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Oct 1993
Decision
123d
Days
Class 2
Risk

K932877 is an FDA 510(k) clearance for the DIASTAT ANTI-CENTROMERE KIT. Classified as Extractable Antinuclear Antibody, Antigen And Control (product code LLL), Class II - Special Controls.

Submitted by Shield Diagnostics, Ltd. (Dundee, GB). The FDA issued a Cleared decision on October 15, 1993 after a review of 123 days - within the typical 510(k) review window.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5100 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Immunology review framework, consistent with the majority of Class II 510(k) submissions.

View all Shield Diagnostics, Ltd. devices

FDA 510(k) Submission Details - K932877

510(k) Number K932877 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 14, 1993
Decision Date October 15, 1993
Days to Decision 123 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary Statement
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
18d slower than avg
Panel avg: 105d · This submission: 123d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

LLL Device Classification - Class 2, Special Controls

Product Code LLL Extractable Antinuclear Antibody, Antigen And Control
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5100
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - LLL Extractable Antinuclear Antibody, Antigen And Control

All 146
Devices cleared under the same product code (LLL) and FDA review panel - the closest regulatory comparables to K932877.
HEMAGEN ENA SCREEN-6 KIT (EIA METHOD)
K935828 · Hemagen Diagnostics, Inc. · Apr 1994
RELISA ENA ANTIBODY SCREENING TEST SYSTEM
K935129 · Immuno Concepts, Inc. · Jan 1994
QUANTA LITE(TM) HISTONE ELISA
K934053 · Inova Diagnostics, Inc. · Dec 1993
SYNELISA JO-1 ANTIBODIES
K930281 · Elias U.S.A., Inc. · Apr 1993
SYNELISA SCL-70 ANTIBODIES
K930417 · Elias U.S.A., Inc. · Apr 1993
QUANTA LITE(TM) JO-1 ELISA KIT
K926562 · Inova Diagnostics, Inc. · Mar 1993